IBI Ag
Last updated: Jul 31, 2026
IBI Ag is an Israeli agricultural-biotechnology startup developing selective bioinsecticides from single-domain antibody (nanobody) technology. Its platform is intended to create new modes of action for controlling sucking and chewing pests while reducing effects on beneficial organisms and the broader environment.
Visit WebsiteCompany Overview
IBI Ag develops biological crop-protection products based on engineered single-domain antibodies, also called nanobodies. The company describes a workflow that selects sensitive proteins and biological functions inside target insects, develops high-affinity binders, and tests candidates for insect-control performance. The small, stable format is adapted from pharmaceutical antibody research but is being developed for agricultural use, where the commercial bar is different: a product must survive field conditions, work at a cost per hectare farmers will accept, fit existing application practices, and satisfy pesticide regulators. The company's stated value proposition is selective control of insect pests, including both sucking and chewing insects, with reduced impact on non-target species. Its website also emphasizes fermentation suitability, which could be important if production can be scaled economically with microbial or other industrial bioprocesses.
The customer problem is concrete. Farmers and crop-protection distributors need additional modes of action as resistance, residue limits, environmental scrutiny, and restrictions on some conventional actives make the product portfolio harder to maintain. IBI Ag has indicated an initial focus on high-value crops, where pest damage is expensive and residue requirements can make differentiated biologicals more valuable, with possible expansion into row crops. Public evidence establishes a platform and development program, not a commercial product launch, approved active ingredient, or recurring revenue base. The Israel Innovation Authority profile identifies agricultural crop producers and farmers as target customers and lists the company at R&D stage. Accordingly, the main near-term milestones are candidate selection, replicated field efficacy, formulation and shelf-life work, regulatory dossiers, manufacturing economics, and distribution or co-development arrangements.
The competitive field includes established biological-control suppliers, microbial and RNA-based biopesticide developers, incumbent crop-protection companies, and non-chemical substitutes such as integrated pest management and beneficial insects. IBI Ag's potential edge is not simply that its molecules are biological: it is the combination of target selectivity, a potentially broad design space for new modes of action, and a claimed path toward fermentation-based production. That edge remains conditional. The company must show that laboratory binding and controlled-environment results translate into consistent performance across pest life stages, crops, climates, application methods, and mixed-field conditions. It must also demonstrate that production, formulation, storage, and application costs can compete with synthetic products and other biologicals after regulatory and channel costs are included. Corteva's leadership of the completed Series A is a meaningful strategic validation signal and could provide domain access, but it is not evidence that a product has been approved, adopted, or commercially launched.
IBI Ag has substantive but bounded dual-use relevance. Crop protection is part of food-system resilience: a country or alliance that can develop and manufacture alternatives to vulnerable pesticide supply chains has more options during trade disruption, resistance events, or sudden pest pressure. A selective product that preserves beneficial insects could also support resilient agricultural production. However, no public source reviewed here documents military customers, defense contracts, classified work, or a direct security application. The strategic case should therefore be framed around agricultural continuity, biological manufacturing capacity, and supply-chain optionality, not battlefield use. The company is an early-stage technology and regulatory diligence opportunity whose value depends on converting a credible platform into registered, field-proven products.
Dual-Use Assessment
IBI Ag's core technology has substantive commercial and strategic applicability, but the strategic case is indirect. Commercially, selective nanobody bioinsecticides could provide new crop-protection modes of action with lower non-target impact. Strategically, domestic capability for alternative pest-control products can support food-system continuity and reduce dependence on concentrated pesticide supply chains during trade disruption or severe pest events. Public evidence does not show military customers, defense contracts, or direct battlefield use, so the dual-use thesis should remain focused on agricultural resilience and biomanufacturing capacity rather than defense procurement.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
IBI Ag is a credible strategic-priority signal for a dual-use and deep-tech database, but not an investment recommendation. The company has a differentiated antibody-based crop-protection approach, a stated route toward fermentation-compatible production, and a completed $10 million Series A led by Corteva Catalyst with participation from other investors and Israel Innovation Authority support. Those signals reduce financing and market-access uncertainty relative to an unbacked laboratory project. The opportunity remains highly execution-dependent: public evidence reviewed here does not establish an approved product, commercial revenue, disclosed customer contracts, or field performance at scale. Diligence should focus on target-pest data, replicated field results, regulatory status and jurisdictional strategy, formulation and shelf life, cost per hectare, manufacturing yield, intellectual-property freedom to operate, and the practical scope of the Corteva relationship. The legacy flag is justified by strategic fit and technical differentiation, while the score is held below the high-priority range because regulatory and commercialization proof is still outstanding.
Strategic Value to U.S.-Israel Alliance
IBI Ag could contribute to food-system resilience by expanding the set of locally developable and manufacturable pest-control options available to farmers and agricultural-input companies. Selective products may help preserve beneficial insects and reduce dependence on some broad-spectrum chemistries, while a platform based on protein engineering and scalable fermentation could build useful industrial-biotechnology capability. The strongest strategic relevance is supply-chain optionality: during trade restrictions, resistance outbreaks, or sudden pest pressure, alternative crop-protection inputs can protect production continuity. This is a resilience and agricultural-security thesis rather than evidence of a defense program. Strategic value will rise materially only if IBI Ag demonstrates repeatable field efficacy, registration in important markets, reliable manufacturing, and distribution or co-development pathways.
Key Technologies
- Engineered single-domain antibody (nanobody) insecticides
- Target-protein discovery and pest-biology screening
- High-affinity, species-selective biological control design
- Fermentation-suitable production of protein actives
- Formulation and field-efficacy development for crop protection
- AI-assisted de novo design of bioinsecticide proteins
Use Cases & Applications
- Selective control of sucking insects in high-value crops
- Selective control of chewing insects while reducing non-target exposure
- Integrated pest-management programs that rotate or supplement conventional modes of action
- Residue-sensitive fruit and vegetable production
- Future row-crop protection if cost and field efficacy are demonstrated
- Domestic and allied agricultural supply resilience during pesticide-chain disruption
- Biological crop-protection development for agricultural-input partners
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 5 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- ibi-ag.com Public source used for profile verification.
- Company announcement Public source used for profile verification.
- innovationisrael.org.il Public source used for profile verification.
- calcalistech.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
IBI Ag may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies IBI Ag's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.